JC02 Rec'd PC PTC 01 SEP 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited via first class mail to U.S. Patent and Trademark Office on the date shown below:

Agata Gliuska

Date:

August 30, 2005

SEP 0 1 2005

Attorney Docket No.: 101141-21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Lia Raquel CHAN et al.

SERIAL NO.

10/520,033

CUSTOMER NO.

27387

FILED

May 2, 2003

FOR

Transcription Factor Gene Induced by Water Deficit

Conditions and Abscisic Acid from Helianthus

Annuus, Promoter and Transgenic Plants

ART UNIT

TBA

EXAMINER

TBA

Mail Stop: Sequence Commissioner for Patents P.O. Box 1450 August 30, 2005

P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

SIR:

On August 9, 2005 my legal assistant, Agata Glinska, spoke with Karen Williams from the Patent Office. It was believed that applicants had previously submitted the sequence listing in paper and electronic form. However, Ms Williams stated that the Patent Office for some reason did not receive the sequence listing in electronic form. Ms. Williams requested the resubmission of the sequence listing in diskette format and to include a paper copy of the sequence listing. Thus, attached is a diskette containing the sequence listing and a paper copy of the sequence listing.

1

The undersigned hereby certifies that the substitute paper copy of the Sequence

Listing does not introduce new matter and certifies that the content of the substitute paper

Sequence Listing and the substitute computer readable form copy is the same and includes
no new matter.

CONDITIONAL PETITION FOR EXTENSION OF TIME

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully request that this be considered a petition therefore. The Assistant Commissioner is authorized to charge any fee(s) due in this connection to Deposit Account No. 14-1263.

ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

CONCLUSION

Early and favorable action is earnestly solicited.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By

Paul & Lim

Attorney for Applicant(s)

Reg. No. 55,383

875 Third Avenue - 18th Floor

New York, New York 10022

Phone: (212) 808-0700

Fax: (212) 808-0844



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. DOX 1450 Alexandria, Viginia 22313-1450

	www.capcago*			
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.		
10/520,033	Lia Raquel Chan	1	01141-21 BSI	1/B
		INTERNATIONAL APPLICATION NO. PCT/US03/13770		
27207	_			
27387 NORRIS, MCLAUGHLIN & MARCUS, P.A.	Г	I.A. FILING DATE	PRIORITY DATE	E
R75 THIRD AVE	_	05/02/2003		

875 THIRD AVE 18TH FLOOR NEW YORK, NY 10022

CONFIRMATION NO. 2792 371 FORMALITIES LETTER

OC000000016444939

Date Mailed: 07/05/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Additionally the following defects have been observed:

• The International Search Report has not be supplied, the basic National Filing Fee has been adjusted to reflect this omission.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

For Rules Interpretation, call (571) 272-0951

- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- . Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

KAREN M WILLIAMS

Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.	
10/520,033	PCT/US03/13770	101141-21	

FORM PCT/DO/EO/922 (371 Formalities Notice)